Africa's HIV/AIDS epidemic could fuel deaths from XDR-TB

Africa's HIV/AIDS epidemic could fuel deaths from XDR-TB -- tuberculosis that is resistant to first- and second-line drugs -- which has resulted in the deaths of least 74 people in South Africa since January 2005, World Health Organization officials said on Tuesday, Reuters reports (McGregor, Reuters, 10/17).

XDR-TB first appeared among HIV-positive people in the South African province of KwaZulu-Natal, according to a study presented in August at the XVI International AIDS Conference in Toronto (Kaiser Daily HIV/AIDS Report, 8/18).

According to experts attending a two-day workshop on XDR-TB and HIV in Johannesburg, South Africa, this week, HIV/AIDS could cause an acceleration of XDR-TB infections and create an uncontrollable epidemic unless control measures are intensified (Dlamini/Dube, BuaNews, 10/17).

"The XDR-TB crisis will not in most parts of the world be solved unless HIV is properly considered," Teguest Guerma of WHO's HIV/AIDS Department said, adding, "Underlying HIV will add significant challenges to the clinical response" (Reuters, 10/17).

Guerma called for HIV and TB programs to have a "close and a real collaboration" (BuaNews, 10/17).

To boost funding to address the XDR-TB outbreak, representatives from the Global Fund To Fight AIDS, Tuberculosis and Malaria plan to redirect current funds to XDR-TB control efforts, and the President's Emergency Plan for AIDS Relief is considering a similar funding shift, Paul Nunn, coordinator of WHO's TB drug-resistance unit, said.

South African Health Minister Manto Tshabalala-Msimang invited government representatives from Lesotho, Malawi, Mauritius, Mozambique, Namibia, Swaziland and Zimbabwe, as well as WHO officials and scientists, to attend the two-day workshop (Reuters, 10/17).


Kaiser Health NewsThis article was reprinted from khn.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New hepatitis B vaccine offers superior protection for people with HIV